SUMMARY Serum angiotensin-converting enzyme activities were measured in 41 type 1 diabetics (16.4 ± 40 U/ml), in 40 type 2 diabetics (15.0 + 5-2 U/ml) and in 52 controls (13-0 + 2-7 U/mi, mean ± SD). Twenty six (32%) of 81 patients presented with serum angiotensin-converting enzyme activities above the normal range. No relation between serum angiotensin-converting enzyme activities and the presence or lack of diabetic vascular diseases in type 1 and type 2 diabetics could be detected. No significant differences in serum angiotensin-converting enzyme activities were found when comparing various types of diabetic vascular disease (retinopathy, neuropathy, renal failure, arterial vascular disease, diabetic vascular disease, coronary artery disease). However, mean serum angiotensin-converting enzyme activities were significantly increased in diabetics with retinopathy when compared with controls (p < 0-0005). Correlation between metabolic long term control as determined by measuring glycohaemoglobin (HbA,) concentrations and serum angiotensin-converting enzyme activities could not be established. Serum angiotensin-converting enzyme activities did not show any correlations with duration of diabetes, age or sex of patients.
In 1975 Lieberman' discovered the association between active sarcoidosis and raised serum angiotensin-converting enzyme activities. Consecutive studies confirmed2-5 the usefulness of serum angiotensin-converting enzyme determination in diagnosis and follow up of sarcoidosis.
In 1980 a possible relation between raised serum angiotensin-converting enzyme activities and diabetes mellitus was reported,6 especially in the investigation of diabetic retinopathy patients. The association between raised serum angiotensin-converting enzyme activity and diabetic microangiopathy could *Presented in part at the XIV Acta Endocrinologica Congress, Stockholm, 27-30 June 1983.
Accepted for publication 23 November 1983 possibly offer an additional diagnostic tool in monitoring diabetic patients. However, in Lieberman's study6 important factors such as type of diabetes, state of metabolic long term control and form of treatment were not taken into consideration when patients with or without vascular complications were evaluated. Therefore, a more extensive investigation of serum angiotensin-converting enzyme was undertaken in diabetes mellitus patients, well defined according to (a) Welch and Boucher.8 The mean (+SD) serum angiotensin-converting enzyme activity in healthy controls was 13-0 + 2-7 U/ml. The upper limit of the normal range (mean + 2 SD) was taken as 18-4 U/ml. Fig. 1 Thus, the precise underlying mechanism for the increased serum angiotensin-converting enzyme activities in 20-40% of diabetics remains to be clarified. In this connection it seems noteworthy that raised angiotensin-converting enzyme activities have been noted in 90% of patients with hyperthyroidism, "3 14 suggesting that endocrinological factors may also be related to an increase in serum angiotensin-converting enzyme activity. Beside sarcoidosis' a variety of diseases-for example, Gaucher's disease,'5 leprosy, '6 Increased serum angiotensin-converting enzyme activities were found in hypertensive patients by one group,2-' findings which -were not confirmed in another study. 24 In the present investigation hypertension was found in only eight of the 30 diabetics (one type 1 diabetes, seven type 2 diabetes) with increased serum angiotensin-converting enzyme ,activities. Thus, it seems unlikely that in diabetics hypertension plays a major role in the raising of serum angiotensin-converting enzyme activity.
The mechanisms for raised activity in serum angiotensin-converting enzyme in about one third of diabetics remains at present unclear. However, our study definitely shows that increased angiotensinconverting enzyme activity cannot be taken as a marker for generalised tissue damage or extensive vascularisation, because (a) angiotensin-converting enzyme activities were increased in only some of the diabetics with microangiopathy and (b) patients with short diabetes duration (< 5 yr) showed similar or even higher angiotensin-converting enzyme activities than patients with longstanding diabetes. This is a strong argument against the hypothesis that even subclinical diabetic vascular injury may raise serum angiotensin-converting enzyme, because the' outcome of late diabetic vascular complications correlates strongly with the duration of disease.25
Although the mechanism responsible for the increase in serum angiotensin-converting enzyme activity in diabetes mellitus remains to be clarified, diabetes should be taken into consideration when raised angiotensin-converting enzyme activities are to be used to confirm the diagnosis of sarcoidosis.
